Nektar Therapeutics (NKTR) reported that its partner Affymax, Inc. announced that the U.S. Food and Drug Administration, or FDA, has approved OMONTYS (peginesatide) injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Nektar and Affymax have an exclusive agreement under which Nektar provides Affymax with its proprietary PEGylation technology for use in OMONTYS. As per the agreement terms, Nektar is entitled to milestones, manufacturing revenues, and royalties on the global sales of OMONTYS.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.